当前位置: 首页 > 详情页

Bevacizumab-based combination therapy in a patient with pseudomyxoma peritonei

文献详情

资源类型:
机构: [1]Department of Internal Medicine/Oncology, Academic Natters Hospital, Natters, Austria [2]Department of Hematology, Xuanwu Hospital, Capital Medical University, Beijing, China [3]Clinical Pathology, Paracelsus Private Medical University of Salzburg, Salzburg, Austria [4]Department of Radiology, Medical University of Innsbruck, Innsbruck, Austria
出处:
ISSN:

关键词: Bevacizumab Metronomic therapy Pseudomyxoma peritonei

摘要:
Effective systemic therapy for advanced pseudomyxoma peritonei (PMP) is the focus of investigation. We describe a case of PMP arising from an adenoma of the appendix in a 58-year-old man. First, the patient underwent explorative laparotomy with ileocoecal resection, but without possibility of major tumour debulking due to adhesive gross tumour masses. Subsequently, six cycles of Folfox IV chemotherapy were administered, without response, but with severe side effects. Upon progressive disease, a combination of bevacizumab and capecitabine led to a long-term stabilization of disease and obvious improvement of performance status. Our case suggests that modulation of tumour microenvironment and angiogenesis by bevacizumab, potentially augmented by monochemotherapy, may be beneficial in borderline tumours such as pseudomyxoma peritonei. © 2009 Springer.

语种:
第一作者:
第一作者机构: [1]Department of Internal Medicine/Oncology, Academic Natters Hospital, Natters, Austria [2]Department of Hematology, Xuanwu Hospital, Capital Medical University, Beijing, China
通讯作者:
通讯机构: [1]Department of Internal Medicine/Oncology, Academic Natters Hospital, Natters, Austria [*1]Department of Internal Medicine, Academic Natters Hospital, In der Stille 20, 6161 Natters, Austria.
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:16461 今日访问量:0 总访问量:871 更新日期:2025-01-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 首都医科大学宣武医院 技术支持:重庆聚合科技有限公司 地址:北京市西城区长椿街45号宣武医院